top of page
Eliminating the burden of anaphylaxis treatment

Eliminating the burden of anaphylaxis treatment

OUR VISION

To prevent avoidable hospitalisations and death from anaphylaxis by removing barriers to the timely administration of adrenaline – the single most important factor in mitigating severe anaphylactic reactions.

Believe in our vision?

Connect with us today.

OUR APPROACH

We are a diverse and passionate team with a united vision of making a true and lasting difference to the lives of anaphylaxis sufferers worldwide. We believe in our product and the positive impact it will have in revolutionising the way anaphylaxis is treated.

THE PROBLEM

globe-icon.png

Est. 156 million people ae affected by anaphylaxis

backpack-icon.png

60% don’t carry their EpiPen

sringe-icon.png

30-45% who do carry refuse to administer

temprature-icon.png

Current solutions are unstable in harsh environments

“Anaphylaxis is a severe, potentially life-threatening allergic reaction that requires immediate treatment with adrenaline (epinephrine). Current treatments like traditional adrenaline injectors, despite their effectiveness, face significant practical issues that limit their use. Patients report issues such as bulkiness of the device, short shelf life, temperature susceptibility, and the hesitation to use it due to needle phobia. Consequently, many patients are either reluctant to carry or use their adrenaline injector, leading to increased risk during an anaphylaxis."

 

Allergy Specialist

OUR SOLUTION

accessible-icon.png
easy-to-use-icon.png
economical-icon.png

“Our product provides a holistic solution, solving all identified problems with current adrenaline delivery systems. Our solution will minimise delayed or absent administration of adrenaline and improve patients' quality of life.”

 

Liam Mahony 


Adracard CEO & Anaphylaxis sufferer

Accessible

Easy to use

Economical

KEY UPDATES

OUR TEAM

EXECUTIVE

Our team is committed to bringing innovative solutions to market.

Dr. Liam Mahony

Founder & CEO

Lachlan Timms

Founder & CTO

Paul Carboon

Executive Director

ADVISORY BOARD

Dr. Katie Allen

Renowned allergy researcher and clinician

Dr. Narinder Singh

ENT

Dr. Paul Wynne

Organic chemist & drug project manager

Eddie Walker

IP attorney for FB Rice

Emma Cleary

Director

Device Technologies

strategic-partnership-section-background-image.jpg

STRATEGIC PARTNERSHIP

We are currently open to investors, partners and advisors who are united in our AdraCard vision to eliminate the burden of anaphylaxis treatment.

Interested in becoming a strategic partner?

We’d love to hear from you!

PROUDLY SUPPORTED BY

Medtech-Actuator-logo.png
Device-Technologies-logo.png
Sebstainable-logo.png
bottom of page